Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Introducing the new face of CLSI M100 in 2023: An explanatory review

8 Aug 2023

Abstract excerpt

BACKGROUND: The CLSI annual update of its M100 document is eagerly awaited every year. This year's update, the M100-Ed33, was published in February, and will significantly affect clinical practices. OBJECTIVE: To highlight and explain the rationale of the changes and their clinical impact. CONTENT: The major changes this year are mostly focused on PK/PD data, selective and cascade reporting of the antibiotics and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotics Pharmacokinetics and Efficacy
Share to Bacterial Identification and Susceptibility Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37945125
DOI: 10.1016/j.ijmmb.2023.100432

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Introducing the new face of CLSI M100 in 2023: An explanatory reviewPMID 37945125Read ↗

Amoxicillin-Clavulanate Breakpoints AgainstEnterobacterales: Rationale for Revision by the Clinical and Laboratory Standards InstituteSemantic proximity Read ↗

Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against EnterobacteralesSemantic proximity Read ↗

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR- P. aeruginosa )Semantic proximity Read ↗

Updating breakpoints in the United States: a summary from the ASM Clinical Microbiology Open 2022Semantic proximity Read ↗

Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosaSemantic proximity Read ↗

P095: The 2nd/3rd generation of cephalosprines use in antimicrobial stewardship program and contemporary carriage of E. coli and K. pneumoniae with esbls from identified or suspected infection hospitalized patientsSemantic proximity Read ↗

Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical LaboratoriesSemantic proximity Read ↗

Bacteria distribution and drug resistance of a tertiary teaching hospital between 2020 and 2021 in Anhui Province, ChinaSemantic proximity Read ↗

Antimicrobial resistance patterns of WHO priority pathogens isolated in hospitalized patients in Japan: A tertiary centre observational studySemantic proximity Read ↗

Imipenem Resistance: A Clarion Call to Antibiotic StewardshipSemantic proximity Read ↗

A Nine-Year Analysis of WHO Critical Priority Pathogens from the Tunisian AMR Surveillance SystemSemantic proximity Read ↗

Suggested Dosing of Select Beta-lactam Agents for the Treatment of Antimicrobial-Resistant Gram-Negative Infections in ChildrenSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.